<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205087</url>
  </required_header>
  <id_info>
    <org_study_id>OKT3-NASH-HMO-CTIL</org_study_id>
    <nct_id>NCT01205087</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome</brief_title>
  <official_title>Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NasVax Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate the safety and immune modulatory effects of oral
      administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PHASE IIa STUDY PROTOCOL A Single-blinded Placebo-controlled Clinical Trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This clinical study is designed to evaluate the safety and the immune-modulatory effects of oral administration of the study drug anti-CD3 MAb to subjects with the metabolic syndrome.</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>This clinical study also will include evaluations for markers of efficacy, as described below.</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OKT3 - 0.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OKT3 - 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OKT3 - 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT3</intervention_name>
    <description>Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>OKT3 - 0.2</arm_group_label>
    <arm_group_label>OKT3 - 1</arm_group_label>
    <arm_group_label>OKT3 - 5</arm_group_label>
    <other_name>Omeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have completed the informed consent process culminating with written
             informed consent by the subject.

          2. Men and women age 18 to 75 years (inclusive)

          3. Patients with biopsy proven NASH within the last 3 years

          4. Altered glucose metabolism, including diabetes (non treated, or treated with up to 2
             drugs (not including insulin) without any change in medication for at least 2 months
             prior to enrollment), impaired fasting glucose or impaired glucose tolerance.

          5. HBA1C between 5.5 and 14%.

        Exclusion Criteria:

          1. Subjects who have undergone surgery within the last 3 months.

          2. Subjects who have had a prior gastrointestinal surgery.

          3. Subjects with a clinically significant infectious, immune mediated or malignant
             disease

          4. Subjects who are receiving an elemental diet or parenteral nutrition.

          5. Subjects who have been treated with any type of immune modulatory drug including
             steroids or NSAID within the last 4 weeks

          6. Subjects who have received either methotrexate or cyclosporine or anti TNF-β
             (infliximab, Remicade), anti-integrin (namixilab) or who have participated in any
             other clinical trial within the last 3 months.

          7. Subjects with a history of coagulopathy.

          8. Women with childbearing potential unless surgically sterile or using adequate
             contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus
             spermicide); pregnant or breastfeeding mothers.

          9. Subjects, who will be unavailable for the duration of the trial, are unlikely to be
             compliant with the protocol, or who are felt to be unsuitable by the investigator for
             any other reason.

         10. Subjects who are HIV-positive.

         11. Subjects who are HBV-positive

         12. Subjects who are HCV-positive.

         13. Subjects with active CMV

         14. Subjects with anemia (Hb &lt;10.5 gm/dl).

         15. Subjects with thrombocytopenia (platelets &lt;100K/µl).

         16. Subjects with lymphopenia (absolute lymphocyte count &lt;0.7).

         17. Subjects with IgG anti-cardiolipin antibody &gt;16 IU.

         18. Prior exposure to anti-CD3 MAb.

         19. Known sensitivity to any ingredients in the study drug

         20. Any know autoimmune disease except for the studied disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah University Hospital, Liver Unit</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gadi Lalazar, M.D.</name_title>
    <organization>Department of Medicine, Hadassah University Hospital, Jerusalem, Israel</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

